Direct Intracerebral Delivery of Cintredekin Besudotox (IL13-PE38QQR) in Recurrent Malignant Glioma: A Report by the Cintredekin Besudotox Intraparenchymal Study Group | Zendy

Sandeep Kunwar | Zendy; Michael D. Prados | Zendy; Susan M. Chang | Zendy; Mitchel S. Berger | Zendy; Frederick F. Lang | Zendy; Joseph M. Piepmeier | Zendy; John H. Sampson | Zendy; Zvi Ram | Zendy; Philip H. Gutin | Zendy; Robert D. Gibbons | Zendy; Kenneth Aldape | Zendy; David Croteau | Zendy; Jeffrey W. Sherman | Zendy; Raj K. Puri | Zendy

Open Access

Direct Intracerebral Delivery of Cintredekin Besudotox (IL13-PE38QQR) in Recurrent Malignant Glioma: A Report by the Cintredekin Besudotox Intraparenchymal Study Group

Author(s) -

Sandeep Kunwar,

Michael D. Prados,

Susan M. Chang,

Mitchel S. Berger,

Frederick F. Lang,

Joseph M. Piepmeier,

John H. Sampson,

Zvi Ram,

Philip H. Gutin,

Robert D. Gibbons,

Kenneth Aldape,

David Croteau,

Jeffrey W. Sherman,

Raj K. Puri

Publication year - 2007

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2006.08.1117

Subject(s) - medicine , tolerability , glioma , surgery , phases of clinical research , intracerebral hemorrhage , adverse effect , chemotherapy , gastroenterology , anesthesia , urology , subarachnoid hemorrhage , cancer research

Glioblastoma multiforme (GBM) is a devastating brain tumor with a median survival of 6 months after recurrence. Cintredekin besudotox (CB) is a recombinant protein consisting of interleukin-13 (IL-13) and a truncated form of Pseudomonas exotoxin (PE38QQR). Convection-enhanced delivery (CED) is a locoregional-administration method leading to high-tissue concentrations with large volume of distributions. We assessed the use of intracerebral CED to deliver CB in patients with recurrent malignant glioma (MG).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research